Prosecution Insights
Last updated: April 19, 2026

Intellia Therapeutics, Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
4
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18415032 Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four REGA, KYLE THOMAS 1636 Final Rejection Jan 17, 2024
18132278 Polynucleotides, Compositions, and Methods for Genome Editing POLIAKOVA-GEORGAN, EKATERINA 1637 Final Rejection Apr 07, 2023
18050333 Methods of in Vitro Cell Delivery ZHU, JIANJIAN 1631 Non-Final OA Oct 27, 2022
17897878 LIPID NANOPARTICLE FORMULATIONS FOR CRISPR/CAS COMPONENTS NGUYEN, QUANG 1631 Final Rejection Aug 29, 2022
17836265 Modified Guide RNAs for Gene Editing ARIETI, RUTH SOPHIA 1635 Non-Final OA Jun 09, 2022
17111769 Modified Guide RNAs for Gene Editing PENNINGTON, KATIE LEIGH 1634 Final Rejection Dec 04, 2020

Managing Intellia Therapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month